search scholar.google.com.

Papers Published

1. Fontes, CM; Lipes, BD; Liu, J; Agans, KN; Yan, A; Shi, P; Cruz, DF; Kelly, G; Luginbuhl, KM; Joh, DY; Foster, SL; Heggestad, J; Hucknall, A; Mikkelsen, MH; Pieper, CF; Horstmeyer, RW; Geisbert, TW; Gunn, MD; Chilkoti, A, Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR., Sci Transl Med, vol. 13 no. 588 (April, 2021), pp. eabd9696 [doi] .
   (last updated on 2024/07/16)

   Abstract:
   Ebola virus (EBOV) hemorrhagic fever outbreaks have been challenging to deter due to the lack of health care infrastructure in disease-endemic countries and a corresponding inability to diagnose and contain the disease at an early stage. EBOV vaccines and therapies have improved disease outcomes, but the advent of an affordable, easily accessed, mass-produced rapid diagnostic test (RDT) that matches the performance of more resource-intensive polymerase chain reaction (PCR) assays would be invaluable in containing future outbreaks. Here, we developed and demonstrated the performance of a new ultrasensitive point-of-care immunoassay, the EBOV D4 assay, which targets the secreted glycoprotein of EBOV. The EBOV D4 assay is 1000-fold more sensitive than the U.S. Food and Drug Administration-approved RDTs and detected EBOV infection earlier than PCR in a standard nonhuman primate model. The EBOV D4 assay is suitable for low-resource settings and may facilitate earlier detection, containment, and treatment during outbreaks of the disease.